GlassScriptPhysician profile
Efesomwan Aisien
NPI 1972867661
$85,738.23
in general payments reported to CMS, 2019-2025
26 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $20K · 2021: $53K · 2022: $8,145 · 2023: $897 · 2024: $2,171 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424 · Consulting Fee: $1,140 · Travel and Lodging: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.26 |
| Consulting Fee | $1,140.00 |
| Travel and Lodging | $428.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $62,356.90 | 2021-2025 | Pillcam, Barrx |
| Covidien LP | $19,967.37 | 2019-2020 | |
| Madrigal Pharmaceuticals | $474.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $366.95 | 2020-2025 | Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $364.45 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.26 | 2019-2024 | Trulance, Xifaxan |
| Gi Supply, INC. | $350.00 | 2020-2021 | |
| Janssen Biotech, INC. | $309.47 | 2022-2025 | Stelara, Tremfya, Remicade |
| Cook Medical LLC | $183.93 | 2019 | |
| Qol Medical, LLC | $151.64 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $131.28 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $113.15 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $108.89 | 2019 | |
| Ardelyx, INC. | $99.64 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $81.33 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48.62 | 2023-2025 | |
| Olympus America INC. | $48.46 | 2025 | Disposable Biopsy Forceps, Olympus, Hanarostent Biliary (Nnn) |
| Braintree Laboratories, INC. | $43.44 | 2020-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $36.94 | 2024 | |
| Lilly USA, LLC | $32.96 | 2023-2024 | Omvoh |
| Dynavax Technologies Corporation | $32.91 | 2023 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $24.06 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $19.09 | 2024 | |
| Pfizer INC. | $15.63 | 2020 | |
| Shionogi INC | $14.49 | 2020 | |
| Allergan, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efesomwan Aisien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.